Session Details
[27-15-pm]Disease Treatment DDS
Thu. Mar 27, 2025 3:10 PM - 4:46 PM JST
Thu. Mar 27, 2025 6:10 AM - 7:46 AM UTC
Thu. Mar 27, 2025 6:10 AM - 7:46 AM UTC
Room 15 (MARINE MESSE FUKUOKA Hall B: Conference Room1-1 [2F])
Chair: Hitoshi Maeda, Akihiro Kishimura
[27-15-pm09S]Antitumor effects of oxaliplatin-containing PEG-coated liposome combined with Rituxan in malignant lymphoma and its effects on phagocytosis of macrophages
○Nanako Kan1, Hidenori Ando1,2, Cristina Nana Amorim Matsuo1, Takaya Sunami1,3, Yusuke Doi3, Haruka Takata1,2, Tatsuhiro Ishida1,2 (1. Pharm. Sci., Tokushima Univ., 2. iDDS, Tokushima Univ., 3. TAIHO Pharm.)
[27-15-pm10]Removing compounds that inhibit lactobacterial activity enhances anti-colitis efficacy
○Cheng Tsai-Ying Hu1, Meng−Shiou Lee1, En-Yu Liu1, Huan−Yuan Chen2, Wen−Huang Peng1, Ming−Kuem Lin1 (1. Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, College of Chinese Medicine, China Medical University, Taichung, Taiwan, R.O.C., 2. Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, R.O.C.)
[27-15-pm11]Investigation of liposome targeting to vascular endothelium in the ischemia/reperfusion region
○Shintaro Yoneda1,2,3, Naoshi Yamazaki2, Masaya Denda2, Akira Otaka2, Kentaro Kogure2,3 (1. Grad. Sch. Pharm. Sci., Tokushima Univ., 2. Grad. Sch. Biomed. Sci., Tokushima Univ., 3. iDDS, Tokushima Univ.)
[27-15-pm12S]Design and evaluation of mRNA-LNPs targeting pancreas and pancreatic β-cells with difficulty in drug delivery
○Yuta Takeuchi1, Yukiko Kaneko2, Takanori Kanazawa1,3 (1. Grad. Sch. Biomed. Sci., Tokushima Univ., 2. Sch. Pharm. Sci., Univ. of Shizuoka, 3. Innovation Research Center for DDS, Tokushima Univ.)
[27-15-pm13S]Design and evaluation of mRNA-LNPs targeting tumors with difficulty in drug delivery
○Natsumi Asakura1, Hiroto Hatakeyama2, Takanori Kanazawa1,3 (1. Grad. Sch. Biomed. Sci., Tokushima Univ., 2. Grad. Sch. Pharm. Sci., Chiba Univ., 3. Innovation Research Center for DDS, Tokushima Univ.)
[27-15-pm14S]Evaluation of the usefulness of Nose-to-Brain Delivery Nanoparticles and Ionic Liquids for Nose-to-Brain Delivery of Heteroduplex Nucleic Acids
○Yurika Kiso1, Shoichiro Fukuda1, Hidefumi Mukai2, Tsuyoshi Tahara3, Tamaki Otani4, Kohta Mohri2, Ikumi Kitahara2, Ayako Matsuo1, Hiroya Kuwahara5, Tetsuya Nagata5, Hidetoshi Hamamoto6, Tatsuhiro Ishida1,7, Takanori Yokota5, Takanori Kanazawa1,7 (1. Grad. Sch. Biomed. Sci., Tokushima Univ. , 2. Grad. Sch. Biomed. Sci., Nagasaki Univ. , 3. TBIS, Tokushima Univ., 4. ARREMC, Tokushima Univ., 5. Grad. Sch. Med and Den. Sci., Science Tokyo., 6. MEDRx, 7. Innovation Research Center for DDS, Tokushima Univ.)
[27-15-pm15S]The development of hepatocyte-specific drug delivery carrier using Hepatitis B virus-like particles (VLP).
○Eri Takayama1, Yuki Iwaisako1, Keiji Ueda2, Masahiro Fujimuro1 (1. Kyoto Pharmaceutical University, 2. Osaka University Graduate School of Medicine)
[27-15-pm16S]Design and Evaluation of PEG Polymer/Functional Peptide Co-assembled Nanoparticles for mRNA Delivery to Brain Nerve via Nose-to-Brain Delivery
○Taku Ikeguchi1, Yasuhiro Kosuge2, Takanori Kanazawa1,3 (1. Grad. Sch. Biomed. Sci., Tokushima Univ., 2. Sch. Pharm. Sci., Nihon Univ., 3. Innovation Research Center for DDS, Tokushima Univ.)